Algorithme Pharma, Inc.

WESTBURY, N.Y., March 7, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence and scientific contributions at the 2024 Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo. This year's conference will be held March 10th-14th in Salt Lake City, Utah. "Our goal at BioIVT is to be our customers' best partner, whether that's providing the biospecimens, cells, and cellular models they need for their internal studies or implementing their sponsored research programs at our facilities," said Dr. Christopher Black, BioIVT Senior Vice President ADME-Tox. "The BioIVT team attending SOT includes experts from across our product portfolios. We look forward to meeting with research colleagues and learning how we can support their programs," he added. As part of its presence at the conference, BioIVT invites attendees to the following scientific sessions: Carboxylesterases in Drug Metabolism: Challenges and Opportunities: BioIVT's Brian Ogilvie, PhD, VP of Scientific Consulting will discuss best practices for in vitro ADME studies with carboxylesterases (CES). His presentation will examine factors affecting the biotransformation and efficacy of drugs and prodrugs that are metabolized by CES, CES-mediated clinical drug-drug interactions (DDI), and the relevant regulatory guidance. The presentation will be held on Tuesday, March 12th from 1:30-2:30pm MT in room 155 E. Sinclair Nanopig: From Multi-Omics Characterization to Pharmacology and Toxicology Validation Underline Drug Metabolism and Immune System: Poster to be presented Thursday, March 14th from 8:30-11:30am MT at Hall E. The poster is based on a research collaboration with Altasciences. "I'm looking forward to discussions with industry colleagues during the conference. At our session on March 12th, at 1:30 pm, I'll outline challenges and opportunities with metabolism by carboxylesterases, important drug-metabolizing enzymes," said Dr. Brian Ogilvie, VP of Scientific Consulting, BioIVT. "I'll provide a high-level overview of in vitro DDI and ADME studies required for CES drug development with a focus on study design and data interpretation, as well as red flags to look for in in vitro DDI study reports," he added. Heading to SOT? Visit BioIVT on the show floor at booth #1509 or schedule a time to connect with us and learn more: About BioIVT BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. We specialize in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®. For more information, please visit or follow us on LinkedIn. BioIVT Contact: Charlie Chungu, Vice President of Marketing, [email protected] Media Contact: Alex Connelly, PAN Communications, 401-486-7437, [email protected] SOURCE BioIVT

Hoth's HT-KIT has received FDA Orphan Drug Status and Continues to Show Positive Study Results in Treating Mast Cell-Derived Cancers NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University. The blood and plasma samples collected are part of a dose response study in a humanized mouse model. The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing. "We continue to make strides in moving HT-KIT from the lab to patients and this further analysis will help us with that process as a final step in the preclinical development that allows us to finalizing the protocols in our upcoming IND-enabling," stated Robb Knie, Chief Executive Officer. "We are pleased to further engage Altasciences on these studies given its great reputation for full-service solutions including preclinical safety testing, clinical pharmacology and bioanalysis." About Hoth Therapeutics, Inc. Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from skin toxicities associated with cancer therapy, mast-cell derived cancers and anaphylaxis, Alzheimer's Disease, atopic dermatitis and other indications. To learn more, please visit . Forward-Looking Statement This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the global economy as a whole; Hoth's intellectual property; Hoth's reliance on third party organizations; Hoth's competitive position; Hoth's industry environment; Hoth's anticipated financial and operating results, including anticipated sources of revenues; Hoth's assumptions regarding the size of the available market, benefits of Hoth's products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding Hoth's goals, intentions, plans and expectations, including the introduction of new products and markets; and Hoth's cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place undue reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U.S. Securities and Exchange Commission. All such statements speak only as of the date of this press release. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. Investor Contact: LR Advisors LLC Email: investorrelations@hoththerapeutics.com Phone: (678) 570-6791 Company Codes: NASDAQ-NMS:HOTH

LAVAL, Québec--(BUSINESS WIRE)-- Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO. This press release features multimedia. View the full release here: From left to right: Altasciences' Dr. Lynne Le Sauteur, Dr. Susan Ohorodnik, Ian Vanterpool, and Michael Qualls at the bioanalytical laboratory opening in Columbia, Missouri (Photo: Business Wire) The newly expanded, 8,000-square-foot space, which includes a test material department, features state-of-the-art equipment and forty-eight workbenches, with a vast range of services, including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities. “This laboratory expansion is a significant step forward in our ability to meet the increasing needs of sponsors. Our focus on growing our bioanalytical capabilities highlights Altasciences' mission to help develop potentially life-saving therapeutics, and get them to market faster,” said Marie-Hélène Raigneau, Co-chief Operating Officer, Altasciences. “Our integrated CRO/CDMO services combine bioanalytical services with preclinical and clinical study solutions, manufacturing services, and all complementary research support services, for maximum efficiency.” This is Altasciences’ third purpose-built laboratory. Altasciences’ laboratory sciences has the scientific, regulatory, and operational expertise for quantitation of drugs and biomarkers from discovery to preclinical to Phase IV, using bioanalysis platforms including mass spectrometry, ligand binding assay, PCR, flow cytometry, ELISpot, and cell based assays in routine and specialized areas such as immunomodulation and cell and gene therapy. All three laboratories across North America are uniformly designed and managed. Whether as a standalone bioanalytical service or as part of an integrated program, Altasciences provides top-quality data for TK, PK, and PD determinations to support preclinical and clinical studies. About Altasciences Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com. View source version on businesswire.com: Contacts Julie-Ann Cabana Altasciences +1 514 601-9763 jcabana@altasciences.com Source: Altasciences Smart Multimedia Gallery Photo From left to right: Altasciences' Dr. Lynne Le Sauteur, Dr. Susan Ohorodnik, Ian Vanterpool, and Michael Qualls at the bioanalytical laboratory opening in Columbia, Missouri (Photo: Business Wire) Logo View this news release and multimedia online at: